Skip to main content
Premium Trial:

Request an Annual Quote

US Regulators Clear GE Healthcare's $580M Purchase of Clarient

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Federal Trade Commission has cleared the way for GE Healthcare's purchase of molecular diagnostics and imaging firm Clarient.

The FTC this week granted GE Healthcare early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, removing antitrust barriers in the US to the cash deal, estimated at $570 million to $580 million.

The proposed acquisition was announced in October. At the time, GE Healthcare said that its diagnostic imaging capabilities combined with Clarient's technologies would hasten development of new integrated tools for diagnosing and characterizing cancer. It added that the global market for cancer-profiling products and services is forecast to increase to $47 million by 2015 from $15 million in 2009.

GE Healthcare has said the deal is expected to close later this year or early in 2011.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.